Partial EdentulismBolivarNCT01529775
Randomized Study of Osseotite Certain Tapered Prevails vs. Osseotite Certain Tapered
A study testing Osseotite Certain Tapered Prevail and Osseotite Certain Tapered in people with Partial Edentulism and Tooth Disease, run by ZimVie at 1 site in Chile.
Trial summary
This study will demonstrate the benefits of platform switching design of the Osseotite dental implant. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Partial Edentulism, Tooth Disease
- What is being tested?
- Osseotite Certain Tapered Prevail and Osseotite Certain Tapered
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 92 participants
- Where
- 1 siteChile
- Study dates
- Nov 2010to Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients of either sex and older than 18 years of age
- patients needing at least one dental implant to treat partial edentulism
- patients physically able to tolerate surgical and restorative dental procedures
- patients agreeing to all protocol visits
Who cannot join
- patients with infection or severe inflammation at the intended treatment sites
- patients smoking greater than 10 cigarettes per day
- patients with uncontrolled diabetes mellitus
- patients with uncontrolled metabolic diseases
- patients who received radiation treatment to the head in the past 12 months
- patients needing bone grafting at the intended treatment sites
- patients known to be pregnant at screening visit
- patients with para-functional habits like bruxing and clenching
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Randomized-controlled Evaluation of the Osseotite Certain Tapered Prevail Implant for the Preservation of Crestal Bone
This study will demonstrate the benefits of platform switching design of the Osseotite dental implant.
Read the detailed description
The Osseotite Certain Prevail implant with its platform switch feature will demonstrate higher success rate than the non-platform Osseotite Certain implant
- Conditions
- Partial Edentulism, Tooth Disease
- Being tested
- Osseotite Certain Tapered Prevail, Osseotite Certain Tapered
- Keywords
- partial edentulism, dental implants, Osseotite Certain Prevail Tapered, Osseotite Certain Tapered, Crestal bone level, randomized, clinical study
- Medical subject headings
- Tooth Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Osseotite Certain Tapered PrevailDevice
Also called Osseotite endosseous dental implant
Osseotite implant with platform switching feature
Osseotite Certain TaperedDevice
Also called Osseotite endosseous dental implant
Osseotite implant with non-platform switching feature
| Study group | Role | What they receive |
|---|---|---|
| Osseotite Certain Tapered Prevail | Experimental | Osseotite Certain Tapered Prevail design with platform switching feature Receives: Device: Osseotite Certain Tapered Prevail |
| Osseotite Certain Tapered | Active comparator | Osseotite Certain Tapered implant with non-platform switching design Receives: Device: Osseotite Certain Tapered |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative Success Rate
An implant will be considered successful if it is immobile when tested at various study time point
Measured: 3 years
Secondary outcomes (1)
Crestal Bone Regression
Differences in crestal bone levels obtained at various study time points will be compared between the two implant designs
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2012 (estimated)
- Study startNov 2010
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Partial EdentulismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- ZimVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Manuel Pavez, DDS, Principal investigator, Finis Terrae University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01529775
- Sponsor's protocol ID
- 3008
- Acronym
- Bolivar
- Status last verified
- Mar 2022
- First submitted
- 7 Feb 2012
- Last updated
- 28 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized-controlled Evaluation of the Osseotite Certain Tapered Prevail Implant for the Preservation of Crestal Bone
- ClinicalTrials.gov ID
- NCT01529775
- Acronym / sponsor ID
- Bolivar / 3008
- Conditions
- Partial Edentulism, Tooth Disease
- Keywords
- partial edentulism, dental implants, Osseotite Certain Prevail Tapered, Osseotite Certain Tapered, Crestal bone level, randomized, clinical study
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- ZimVieIndustry (pharma, biotech, devices)
- Study start
- Nov 2010
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 9 Feb 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will demonstrate the benefits of platform switching design of the Osseotite dental implant.
Detailed description
The Osseotite Certain Prevail implant with its platform switch feature will demonstrate higher success rate than the non-platform Osseotite Certain implant
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Osseotite Certain Tapered Prevail | Experimental | Device: Osseotite Certain Tapered PrevailOsseotite Certain Tapered Prevail design with platform switching feature |
| Osseotite Certain Tapered | Active comparator | Device: Osseotite Certain TaperedOsseotite Certain Tapered implant with non-platform switching design |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patients of either sex and older than 18 years of age
- patients needing at least one dental implant to treat partial edentulism
- patients physically able to tolerate surgical and restorative dental procedures
- patients agreeing to all protocol visits
Key exclusion criteria (8 listed)
- patients with infection or severe inflammation at the intended treatment sites
- patients smoking greater than 10 cigarettes per day
- patients with uncontrolled diabetes mellitus
- patients with uncontrolled metabolic diseases
- patients who received radiation treatment to the head in the past 12 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Osseotite Certain Tapered PrevailAlso: Osseotite endosseous dental implantOsseotite implant with platform switching feature | Device | Osseotite Certain Tapered Prevail |
| Osseotite Certain TaperedAlso: Osseotite endosseous dental implantOsseotite implant with non-platform switching feature | Device | Osseotite Certain Tapered |
Primary outcome
Cumulative Success Rate
Time frame: 3 years
An implant will be considered successful if it is immobile when tested at various study time point
1 secondary outcome
Crestal Bone Regression
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2022.
- Individual participant dataSharing planned: No
Related trials for Partial Edentulism
Not yet recruitingObservational study
Digital and Conventional Clasp-retained Partial Dentures (DIGICLASP)
Partial Edentulism
Not yet recruiting
Comparative Evaluation of Artificial Intelligence-Assisted Versus Conventional Guided Implant Planning in Free End Saddle Cases
Partial Edentulism Class 1 or Class 2
Not yet recruiting
Immediate vs Conventional Loading With Different Crown Materials on Immediately Placed Single Implants
Partial Edentulism, Dental Implant
Active, not recruiting
Clinical Fit of Conventionally Cast and 0° SLM Removable Partial Denture Frameworks
Partial Edentulism Class 3, Removable Partial Denture
Active, not recruitingObservational study
Survival of Implant-Supported All-Ceramic Prostheses
Partial Edentulism, Disorder of Prostheses and Implants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manuel Pavez, DDS principal investigator
Finis Terrae University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Osseotite Certain Tapered Prevail and Osseotite Certain Tapered in people with Partial Edentulism and Tooth Disease, run by ZimVie at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative Success Rate (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2022.